Preliminary results of this nonrandomized study suggest that 2 doses of the HZ/su vaccine produce satisfactory antibody responses and acceptable tolerability in a majority of patients with RA receiving JAK inhibitors.
In a cohort of US patients with RA, neither an increased incidence of cardiac events nor increased mortality was observed with use of HCQ.
In early RA, pharmacogenomics biomarkers may be useful in guiding effective RA treatment choices and need for treatment escalation.
Flares more frequent with tapered vs continued TNF inhibitor during first 12 months (63% vs 5%, respectively).
Pooled analysis of 5 phase III trials in RA suggests that history of VTE and higher BMI were risk factors for VTE in those receiving upadacitinib.
In cross-trial post hoc analysis with mixed-effect model repeated measure adjustment, no evident differences in Week 24 endpoints (CDAI, DAS28-CRP, CRP, hemoglobin, pain VAS, FACIT-Fatigue) between patients receiving sarilumab with vs without MTX.
Pooled analysis of 7 phase II/III trials suggests that the investigational JAK inhibitor is associated with low rates of VTE and MACE, with no major safety signals among those with cardiovascular risk factors.
After first year of follow-up, no progression to inflammatory arthritis observed for 44% to 68% of ACPA-positive individuals, 66% to 89% of ACPA-negative individuals across cohorts.
Pooled analysis of 2 North American cohorts finds high agreement between physicians and patients in distinguishing between active vs controlled RA.
At Week 48, SDAI remission maintained in 49.5% of patients receiving etanercept monotherapy vs 28.7% of patients receiving methotrexate monotherapy.